National Institute on Drug Abuse; Notice of Closed Meetings, 4010-4011 [2023-01191]
Download as PDF
<![CDATA[
4010
Federal Register / Vol. 88, No. 14 / Monday, January 23, 2023 / Notices
AND
U.S. Department of Health and
Human Services, Office of Inspector
General, ATTN: Mandatory Grant
Disclosures, Intake Coordinator, 330
Independence Avenue SW, Cohen
Building, Room 5527, Washington, DC
20201, URL: https://oig.hhs.gov/fraud/
report-fraud/, (Include ‘‘Mandatory
Grant Disclosures’’ in subject line), Fax:
(202) 205–0604 (Include ‘‘Mandatory
Grant Disclosures’’ in subject line) or,
Email: MandatoryGranteeDisclosures@
oig.hhs.gov.
Failure to make required disclosures
can result in any of the remedies
described in 45 CFR 75.371 Remedies
for noncompliance, including
suspension or debarment (see 2 CFR
part 180 and 2 CFR part 376).
VII. Agency Contacts
1. Questions on the programmatic
issues may be directed to: Debi
Nalwood, Health System Specialist,
Indian Health Service, Office of Urban
Indian Health Programs, 5600 Fishers
Lane, Mail Stop: 08E65D, Rockville, MD
20857, Phone: (240) 701–0882, Email:
Debiallison.Nalwood@ihs.gov.
2. Questions on grants management
and fiscal matters may be directed to:
Pallop Chareonvootitam, Grants
Management Specialist, Indian Health
Service, Division of Grants
Management, 5600 Fishers Lane, Mail
Stop: 09E70, Rockville, MD 20857,
Phone: (301) 443–2195, Email:
Pallop.Chareonvootitam@ihs.gov.
3. Questions on systems matters may
be directed to: Paul Gettys, Deputy
Director, Division of Grants
Management, Indian Health Service,
Division of Grants Management, 5600
Fishers Lane, Mail Stop: 09E70,
Rockville, MD 20857, Phone: (301) 443–
2114; or the DGM main line (301) 443–
5204, E-Mail: Paul.Gettys@ihs.gov.
khammond on DSKJM1Z7X2PROD with NOTICES
VIII. Other Information
The Public Health Service strongly
encourages all grant, cooperative
agreement, and contract recipients to
provide a smoke-free workplace and
promote the non-use of all tobacco
products. In addition, Public Law 103–
227, the Pro-Children Act of 1994,
prohibits smoking in certain facilities
(or in some cases, any portion of the
facility) in which regular or routine
education, library, day care, health care,
or early childhood development
services are provided to children. This
is consistent with the HHS mission to
VerDate Sep<11>2014
16:44 Jan 20, 2023
Jkt 259001
protect and advance the physical and
mental health of the American people.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
P. Benjamin Smith,
Deputy Director, Indian Health Service.
National Institutes of Health
[FR Doc. 2023–01150 Filed 1–20–23; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; A Multi-omics Approach to
Immune Responses in HIV Vaccination and
Intervention (P01 Clinical Trial Not
Allowed).
Date: February 15–16, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G21A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Dimitrios N. Vatakis,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G21A,
Rockville, MD 20852, 301–761–7176,
dimitrios.vatakis@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01195 Filed 1–20–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
Research Study Section Microbiology and
Infectious Diseases Research Study Section.
Date: February 21–22, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G62,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Eleazar Cohen, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institute of Health, 5601
Fishers Lane, Room 3G62A, Bethesda, MD
20892, (240) 669–5081, ecohen@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01192 Filed 1–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
E:\FR\FM\23JAN1.SGM
23JAN1
Federal Register / Vol. 88, No. 14 / Monday, January 23, 2023 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Stimulants and HIV: Addressing
Contemporary and Recurring Epidemics.
Date: March 1, 2023.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Marisa Srivareerat, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 435–1258,
marisa.srivareerat@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Reaching Equity at the Intersection of HIV
and Substance Use.
Date: March 6, 2023.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Marisa Srivareerat, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 435–1258,
marisa.srivareerat@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIH
Blueprint for Neuroscience Research:
Computational Training in Neuroscience and
Behavior.
Date: March 14, 2023.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
VerDate Sep<11>2014
16:44 Jan 20, 2023
Jkt 259001
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: January 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01191 Filed 1–20–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
B Research Study Section Microbiology and
Infectious Diseases B Subcommittee.
Date: March 1–3, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
5601 Fishers Lane, Room 3F58, Rockville,
MD 20892, 240–669–5199, cerritem@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01193 Filed 1–20–23; 8:45 am]
BILLING CODE 4140–01–P
Frm 00046
Fmt 4703
ADVISORY COUNCIL ON HISTORIC
PRESERVATION
Exemption From Historic Preservation
Review for General Services
Administration Routine Operations and
Maintenance
Advisory Council on Historic
Preservation.
ACTION: Approval of exemption.
AGENCY:
The Advisory Council on
Historic Preservation has approved an
exemption that relieves the General
Services Administration from historic
preservation review requirements under
the National Historic Preservation Act
for specified routine operations and
maintenance activities.
DATES: The exemption went into effect
on January 13, 2023.
FOR FURTHER INFORMATION CONTACT:
Laura Lavernia, (202) 517–0225,
llavernia@achp.gov.
SUPPLEMENTARY INFORMATION: Section
106 of the National Historic
Preservation Act (section 106) requires
federal agencies to take into account the
effects of projects, activities, or
programs they carry out, license, or
assist on historic properties
(undertakings) and afford the Advisory
Council on Historic Preservation
(ACHP) a reasonable opportunity to
comment with regard to such
undertakings. Historic properties are
those that are listed or have been
determined eligible for listing in the
National Register of Historic Places
(NRHP).
The National Historic Preservation
Act (NHPA) authorizes the ACHP to
promulgate regulations for exempting
undertakings ‘‘from any or all the
requirements of’’ the NHPA. The section
106 implementing regulations, 36 CFR
800, detail the process for the approval
of such exemptions.
In accordance with 36 CFR
800.14(c)(1), the ACHP may approve an
exemption for an undertaking if it finds
that: (i) the actions within the program
or category would otherwise qualify as
‘‘undertakings’’ as defined in 36 CFR
800.16; (ii) the potential for effects of
the undertakings within the program or
category upon historic properties are
foreseeable and likely to be minimal or
not adverse; and (iii) exemption of the
program or category is consistent with
the purposes of the NHPA.
SUMMARY:
BILLING CODE 4140–01–P
PO 00000
4011
Sfmt 4703
I. Background
General Services Administration (GSA)
Use of 36 CFR 800.14 for Regional
Routine Operations and Maintenance
In accordance with the regulations
and processes outlined in 36 CFR
E:\FR\FM\23JAN1.SGM
23JAN1
]]>Agencies
[Federal Register Volume 88, Number 14 (Monday, January 23, 2023)]
[Notices]
[Pages 4010-4011]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01191]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
[[Page 4011]]
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Stimulants and HIV: Addressing Contemporary and
Recurring Epidemics.
Date: March 1, 2023.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Marisa Srivareerat, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 435-1258,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Reaching Equity at the Intersection of HIV and
Substance Use.
Date: March 6, 2023.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Marisa Srivareerat, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 435-1258,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIH Blueprint for Neuroscience Research:
Computational Training in Neuroscience and Behavior.
Date: March 14, 2023.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: January 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-01191 Filed 1-20-23; 8:45 am]
BILLING CODE 4140-01-P
